Steven L Driver, MD
Interventional Cardiology · Chicago
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
Offices
6 locations · Advocate Health and Hospitals Corporation · 3,081 clinicians in this group
Hospitals listed: Advocate Illinois Masonic Medical Center · Advocate Lutheran General Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Driver’s office to ask if they take your plan before you enroll.
State licence records
1 licence
- Illinois 036132886Licensed Physician And Surgeon · since 2013 · expires 2029-07-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Advocate Illinois Masonic Medical CenterChicago, ILAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Advocate Health, which runs 58 hospitals in 6 statesPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.42 (1.08 to 1.76), Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 17.29 (10.23 to 24.34) · 361 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.29 (5.61 to 12.98) · 356 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.4 (12.4 to 16.7) · 740 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.429, Oct 2024 – Sep 2025
- Advocate Lutheran General HospitalPark Ridge, ILAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Advocate Health, which runs 58 hospitals in 6 statesPatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.5 (10.8 to 16.6) · 325 cases, Jan 2024 – Dec 2024Better than the national rate — Pressure ulcer rate: 0.2 (0 to 0.6) · 12,230 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.422, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.367, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.498, Oct 2024 – Sep 2025
See every measure and the patient survey for Advocate Illinois Masonic Medical Center
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.42 (1.08 to 1.76) | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 17.29 (10.23 to 24.34) · 361 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 9.29 (5.61 to 12.98) · 356 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.4 (12.4 to 16.7) · 740 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.429 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.31 (0.34 to 2.29) · 746 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 170.84 (118.4 to 223.28) · 68 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.6 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 62 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.1 · 269 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 183 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 147 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 2,220 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.07 to 0.51) · 3,801 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.43) · 3,798 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.99 (1.85 to 6.13) · 938 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.62 (1.03 to 4.22) · 356 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.05 (0.53 to 3.57) · 865 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 226 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.65 (0 to 1.39) · 3,096 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.3 · 38 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.399 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.139 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.254 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.896 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14 · 123 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 584 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 0.4 · 61 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19 · 305 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 19.7 · 199 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 345 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.1 (3.2 to 5.4) · 740 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.8 · 39 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.2 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.5 · 95 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (9.6 to 16.5) · 1,028 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 304 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,107 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Advocate Lutheran General Hospital
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.8 to 16.6) · 325 cases | Worse | Jan 2024 – Dec 2024 |
| Pressure ulcer rateComplications and deaths | 0.2 (0 to 0.6) · 12,230 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.422 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.367 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.498 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.58 (0 to 1.39) · 2,497 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.63 to 1.07) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 144.39 (110.97 to 177.81) · 194 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 75 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.7 · 183 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.5 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 1,210 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.4 · 1,211 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.8 · 762 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 6,370 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.3 (0.12 to 0.47) · 13,662 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.05 to 0.39) · 13,907 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.05 (1.43 to 4.66) · 3,062 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.91 (0.55 to 3.27) · 1,359 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.08 to 3.64) · 2,827 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.82 (3.33 to 12.31) · 1,321 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.48 (3.61 to 9.35) · 1,294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.51 (0.09 to 2.92) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 93 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.073 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.782 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.956 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 290 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.3 · 1,571 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -3.7 · 232 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 9 · 1,358 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.7 · 1,251 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.3 · 1,523 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.4 (3.1 to 6.1) · 325 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 104 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.4 · 103 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 223 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.3 (10.7 to 16.3) · 3,296 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 957 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,055 patients answered, 22% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$43,560
Medicare paid this office $43,560 for 199 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 77 | $9,246 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $5,684 | $135 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,845 | $63 |
| New patient visit (45+ min) | 21 | $2,700 | $129 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 11 | $2,588 | $235 |
See all 11 services
| Return visit (30+ min) | 77 | $9,246 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $5,684 | $135 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,845 | $63 |
| New patient visit (45+ min) | 21 | $2,700 | $129 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 11 | $2,588 | $235 |
| Short return visit (20+ min) | 26 | $2,096 | $72 |
| New patient visit (60+ min) | 14 | $1,840 | $131 |
| Long return visit (40+ min) | 12 | $1,191 | $99 |
| Insertion of needle into vein for collection of blood sample | 39 | $389 | $9 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 33 | $348 | $10 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 24 | $310 | $12 |
Procedures Medicare counted
| Coronary angioplasty and stenting | 1-10 | None |
| Pacemaker insertion or repair | 1-10 | None |
Who their Medicare patients are
199 Original Medicare patients in 2024. Average age 76 · Under 65 7% · 85 and older 17% · Women 46% · Also on Medicaid 29% · Health risk score 1.96. Above the middle of the specialty; the typical interventional cardiology clinician is at 1.7.
Conditions among them: High blood pressure 75% · Coronary heart disease 73% · Heart failure 53% · Chronic kidney disease 47% · Atrial fibrillation 44% · Diabetes 43% · Depression 28% · COPD 22% · Cancer 14% · Dementia 14% · Stroke 14%.
The office billed $167,283, Medicare allowed $56,244 and paid $43,560; for 462 services of 42 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 199 | 462 | 76 | 1.96 | $167,283 | $43,560 |
| 2023 | 183 | 425 | 76 | 1.81 | $215,605 | $47,777 |
| 2022 | 199 | 448 | 74 | 2.10 | $215,918 | $52,800 |
| 2021 | 234 | 632 | 76 | 1.83 | $341,843 | $78,393 |
| 2020 | 192 | 521 | 75 | 1.93 | $257,240 | $58,353 |
| 2019 | 251 | 587 | 75 | 2.16 | $272,088 | $66,817 |
| 2018 | 65 | 113 | 72 | 2.37 | $46,889 | $12,579 |
| 2014 | 48 | 51 | 74 | 2.49 | $15,869 | $6,129 |
| 2013 | 44 | 62 | 76 | 1.63 | $8,439 | $3,550 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Return visit (30+ min) | 48 | $6,207 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $5,108 | $142 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $2,909 | $61 |
| Short return visit (20+ min) | 26 | $1,808 | $67 |
| New patient visit (60+ min) | 12 | $1,791 | $149 |
| New patient visit (45+ min) | 11 | $1,534 | $139 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 28 | $329 | $11 |
| Insertion of needle into vein for collection of blood sample | 30 | $294 | $8 |
2022: 10 services
| Return visit (30+ min) | 81 | $10,136 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $4,829 | $167 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 14 | $3,703 | $231 |
| Long return visit (40+ min) | 21 | $2,767 | $126 |
| New patient visit (60+ min) | 13 | $2,279 | $175 |
| New patient visit (60+ min) | 11 | $1,770 | $161 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $1,553 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,464 | $86 |
| Short return visit (20+ min) | 20 | $1,396 | $66 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 34 | $416 | $11 |
2021: 16 services
| Return visit (30+ min) | 77 | $11,243 | $104 |
| Replacement of aortic valve through the skin and femoral artery | 13 | $9,088 | $699 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $5,873 | $88 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 21 | $4,882 | $222 |
| New patient visit (60+ min) | 26 | $4,860 | $187 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,744 | $170 |
| Long return visit (40+ min) | 27 | $3,657 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,626 | $61 |
| Long return visit (40+ min) | 12 | $1,757 | $146 |
| Return visit (30+ min) | 17 | $1,543 | $86 |
| New patient visit (45+ min) | 11 | $1,448 | $132 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,277 | $116 |
| Short return visit (20+ min) | 14 | $1,097 | $78 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 17 | $1,002 | $59 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 11 | $956 | $87 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 46 | $539 | $11 |
2020: 10 services
| Return visit (30+ min) | 57 | $6,038 | $81 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 13 | $3,715 | $219 |
| New patient visit (60+ min) | 21 | $3,563 | $170 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $3,334 | $61 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,283 | $86 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 18 | $1,174 | $62 |
| New patient visit (45+ min) | 11 | $1,065 | $97 |
| Return visit (30+ min) | 11 | $862 | $62 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 21 | $237 | $11 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 16 | $205 | $13 |
2019: 11 services
| Replacement of aortic valve through the skin and femoral artery | 11 | $8,958 | $814 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 50 | $8,925 | $168 |
| Return visit (30+ min) | 59 | $7,138 | $86 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 20 | $4,923 | $246 |
| New patient visit (45+ min) | 28 | $3,652 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 43 | $3,594 | $59 |
| New patient visit (60+ min) | 16 | $2,330 | $146 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 38 | $2,255 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,604 | $89 |
| Ultrasonic guidance for blood vessel access | 15 | $212 | $12 |
| Blood test, clotting time | 11 | $158 | $4 |
2018: 1 service
| New patient visit (45+ min) | 11 | $1,534 | $139 |
2014: 2 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,416 | $161 |
| Initial hospital observation care per day, typically 50 minutes | 13 | $1,487 | $114 |
2013: 1 service
| Short return visit (20+ min) | 13 | $547 | $42 |
Medicaid work
$1,434 in 2024
Medicaid paid $1,434 for 35 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| 1ST HOSP IP/OBS HIGH 75 | 14 | $872 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 21 | $562 |
| 2024 | 35 | 2 | 16 | $1,434 |
| 2022 | 25 | 1 | 13 | $836 |
See the largest Medicaid services in earlier years
2022
| Return visit (30+ min) | 25 | $836 |
Drugs they prescribed that Part D paid
$368,100
Pharmacies billed $368,100 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,559) in 2024. At or below the middle of the specialty; the typical interventional cardiology clinician is at 0%.
1,342 generic and 217 brand-name prescriptions · $368,100 in drug cost · 16 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Camzyos | 18 | $141,784 | $7,877 |
| Eliquis | 111 | $105,880 | $954 |
| Jardiance | 24 | $36,792 | $1,533 |
| Xarelto | 18 | $29,843 | $1,658 |
| Vascepa | 19 | $12,650 | $666 |
See all 23 drugs
| Camzyos | 18 | $141,784 | $7,877 |
| Eliquis | 111 | $105,880 | $954 |
| Jardiance | 24 | $36,792 | $1,533 |
| Xarelto | 18 | $29,843 | $1,658 |
| Vascepa | 19 | $12,650 | $666 |
| Atorvastatin | 287 | $2,904 | $10 |
| Rosuvastatin | 148 | $2,732 | $18 |
| Metoprolol | 148 | $1,795 | $12 |
| Icosapent Ethyl | 11 | $1,690 | $154 |
| Ezetimibe | 54 | $1,454 | $27 |
| Carvedilol | 112 | $1,234 | $11 |
| Clopidogrel | 63 | $771 | $12 |
| Chlorthalidone | 40 | $716 | $18 |
| Losartan | 84 | $695 | $8 |
| Lisinopril | 97 | $580 | $6 |
| Amlodipine Besylate | 104 | $528 | $5 |
| Enalapril Maleate | 15 | $180 | $12 |
| Hydrochlorothiazide | 20 | $115 | $6 |
| Furosemide | 26 | $112 | $4 |
| Spironolactone | 25 | $76 | $3 |
| Metoprolol | 16 | $49 | $3 |
| Warfarin | 11 | $46 | $4 |
| Amoxicillin | 11 | $12 | $1 |
Year by year
| 2024 | 1,559 | 264 | 0% (0) | 14% | $368,100 |
| 2023 | 1,579 | 254 | 0% (0) | 10% | $337,601 |
| 2022 | 1,477 | 248 | 0% (0) | 12% | $210,629 |
| 2021 | 1,430 | 259 | 0% (0) | None | $185,371 |
| 2020 | 1,206 | 239 | 0% (0) | 15% | $135,728 |
| 2019 | 860 | 193 | 0% (0) | 12% | $75,799 |
| 2018 | 77 | 35 | 0% (0) | None | $4,186 |
| 2015 | 11 | None | None | None | $1,547 |
| 2014 | 21 | None | 0% (0) | None | $416 |
| 2013 | 144 | 42 | None | 13% | $4,833 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 22 drugs
| Camzyos | 17 | $144,990 | $8,529 |
| Eliquis | 49 | $57,879 | $1,181 |
| Jardiance | 32 | $39,291 | $1,228 |
| Xarelto | 23 | $31,090 | $1,352 |
| Vascepa | 17 | $10,862 | $639 |
| Icosapent Ethyl | 29 | $7,807 | $269 |
| Atorvastatin | 284 | $5,369 | $19 |
| Rosuvastatin | 132 | $3,265 | $25 |
| Metoprolol | 154 | $2,841 | $18 |
| Ezetimibe | 35 | $2,431 | $69 |
| Chlorthalidone | 53 | $1,623 | $31 |
| Carvedilol | 125 | $1,596 | $13 |
| Amlodipine Besylate | 131 | $1,478 | $11 |
| Losartan | 92 | $1,336 | $15 |
| Clopidogrel | 76 | $1,095 | $14 |
| Lisinopril | 100 | $870 | $9 |
| Enalapril Maleate | 22 | $322 | $15 |
| Warfarin | 16 | $308 | $19 |
| Metoprolol | 16 | $244 | $15 |
| Furosemide | 41 | $136 | $3 |
| Spironolactone | 19 | $136 | $7 |
| Hydrochlorothiazide | 13 | $63 | $5 |
2022: 20 drugs
| Eliquis | 66 | $74,182 | $1,124 |
| Xarelto | 29 | $36,897 | $1,272 |
| Jardiance | 16 | $17,347 | $1,084 |
| Vascepa | 14 | $6,957 | $497 |
| Rosuvastatin | 117 | $5,317 | $45 |
| Icosapent Ethyl | 16 | $4,838 | $302 |
| Atorvastatin | 297 | $4,555 | $15 |
| Metoprolol | 142 | $3,018 | $21 |
| Chlorthalidone | 52 | $1,433 | $28 |
| Ezetimibe | 23 | $1,416 | $62 |
| Carvedilol | 142 | $1,315 | $9 |
| Amlodipine Besylate | 120 | $910 | $8 |
| Clopidogrel | 61 | $908 | $15 |
| Losartan | 82 | $862 | $11 |
| Lisinopril | 92 | $672 | $7 |
| Isosorbide Mononitrate Er | 15 | $404 | $27 |
| Furosemide | 20 | $139 | $7 |
| Hydrochlorothiazide | 14 | $124 | $9 |
| Spironolactone | 14 | $100 | $7 |
| Amoxicillin | 11 | $36 | $3 |
2021: 15 drugs
| Eliquis | 83 | $81,610 | $983 |
| Xarelto | 17 | $23,511 | $1,383 |
| Trulicity | 14 | $21,722 | $1,552 |
| Atorvastatin | 300 | $5,219 | $17 |
| Rosuvastatin | 101 | $5,017 | $50 |
| Metoprolol | 131 | $3,010 | $23 |
| Ezetimibe | 26 | $1,478 | $57 |
| Carvedilol | 152 | $1,395 | $9 |
| Clopidogrel | 87 | $1,080 | $12 |
| Amlodipine Besylate | 126 | $1,012 | $8 |
| Chlorthalidone | 37 | $873 | $24 |
| Losartan | 74 | $796 | $11 |
| Lisinopril | 96 | $559 | $6 |
| Furosemide | 16 | $120 | $7 |
| Spironolactone | 11 | $76 | $7 |
2020: 19 drugs
| Eliquis | 49 | $42,605 | $869 |
| Xarelto | 19 | $19,806 | $1,042 |
| Trulicity | 19 | $19,569 | $1,030 |
| Chantix | 17 | $12,934 | $761 |
| Atorvastatin | 237 | $4,458 | $19 |
| Rosuvastatin | 86 | $3,989 | $46 |
| Metoprolol | 93 | $2,377 | $26 |
| Chlorthalidone | 41 | $1,808 | $44 |
| Carvedilol | 112 | $1,389 | $12 |
| Lisinopril | 113 | $963 | $9 |
| Ezetimibe | 13 | $934 | $72 |
| Amlodipine Besylate | 93 | $822 | $9 |
| Clopidogrel | 56 | $772 | $14 |
| Losartan | 51 | $568 | $11 |
| Enalapril Maleate | 11 | $486 | $44 |
| Spironolactone | 29 | $385 | $13 |
| Furosemide | 23 | $292 | $13 |
| Ramipril | 19 | $195 | $10 |
| Metoprolol | 15 | $122 | $8 |
2019: 14 drugs
| Eliquis | 27 | $32,835 | $1,216 |
| Xarelto | 23 | $18,442 | $802 |
| Atorvastatin | 195 | $4,534 | $23 |
| Rosuvastatin | 63 | $3,701 | $59 |
| Chlorthalidone | 36 | $2,011 | $56 |
| Metoprolol | 65 | $1,727 | $27 |
| Amlodipine Besylate | 91 | $866 | $10 |
| Lisinopril | 80 | $688 | $9 |
| Carvedilol | 63 | $637 | $10 |
| Losartan | 37 | $531 | $14 |
| Furosemide | 32 | $276 | $9 |
| Clopidogrel | 19 | $210 | $11 |
| Spironolactone | 20 | $153 | $8 |
| Hydrochlorothiazide | 12 | $74 | $6 |
2018: 2 drugs
| Atorvastatin | 16 | $372 | $23 |
| Amlodipine Besylate | 11 | $90 | $8 |
2013: 1 drug
| Hydrochlorothiazide | 13 | $71 | $5 |
Money from drug and device companies
$301 in 2025
| 2025 | 3 | 3 | None | $301 |
| 2024 | 2 | 4 | None | $127 |
| 2023 | 4 | 5 | None | $166 |
| 2022 | 5 | 8 | None | $207 |
| 2021 | 2 | 5 | None | $321 |
| 2020 | 2 | 2 | None | $47 |
| 2019 | 4 | 14 | None | $738 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Shockwave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $155 | 1 payment
|
| Abbott Laboratories | Mitraclip | $122 | 1 payment
|
| Edwards Lifesciences | None | $23 | 1 payment
|
See all 3 published payments
| Shockwave Medical | Meals · 2025-12-03 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $155 |
| Edwards Lifesciences | Meals · 2025-03-19 | None | $23 |
| Abbott Laboratories | Meals · 2025-01-06 | Mitraclip | $122 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $127
| Teleflex | Guideliner | $64 | 2 payments
|
| Current Health | None | $63 | 2 payments
|
2023: $166
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $122 | 2 payments
|
| Opsens | Optowire | $16 | 1 payment
|
| Current Health | None | $15 | 1 payment
|
| Medtronic | Corevalve Evolut R | $14 | 1 payment
|
2022: $207
| Boston Scientific | Synergy | $117 | 4 payments
|
| Abiomed | Impella | $28 | 1 payment
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $28 | 1 payment
|
| Siemens Medical Solutions USA | Artis Q Ceiling | $19 | 1 payment
|
| Abbott Laboratories | Cardiomems | $15 | 1 payment
|
2021: $321
| Abiomed | Impella | $185 | 4 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $136 | 1 payment
|
2020: $47
| Medtronic Vascular | Corevalve Evolut | $30 | 1 payment
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve | $17 | 1 payment
|
2019: $738
| Abbott Laboratories | Mitra Clip System | $500 | 10 payments
|
| Abiomed | Impella | $199 | 2 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve | $23 | 1 payment
|
| Boston Scientific | Watchman | $15 | 1 payment
|
Professional record
- NPI
- 1104147628
- Licence
- IL 036-132886, MN 54091Illinois 036132886: Active
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- IA ENROLLED, MN ENROLLED, WI ENROLLED
- Taxonomy
- Federal specialty code 207RI0011X (207RI0011X); Internal medicine (207R00000X)
- Mailing address
- 29373 Network Pl, Chicago, IL, 60673
- NPI first listed
- 2010-06-18
- NPI last updated
- 2022-09-27
- NPI record certified
- 2022-09-27
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.